Vol. 12, Issue 8 (2023)

Author(s):
Pravas Ranjan Sahoo, Jyochhna Rani Sahoo, Usharani Sahoo, Ambika Nayak and Prabhat Kumar Padhi

Abstract:
Severe acute respiratory syndrome-corona virus 2 (SARS-CoV-2) is one important cause of global COVID-19 pandemic, resulting lakhs of infections and thousands of mortalities in the world. RNA dependant RNA polymerase (RdRp) is one important enzyme of corona virus, mediates both replication as well as the transcription of the virus, would be primary target for various antiviral drugs. Galidesivir is an adenosine analogue which inhibits the RNA polymerase promises one important antiviral drug candidate against SARS-CoV2.In this study, the binding interaction between protein target and Galidesivir was done under Auto Dock platform The best docked Galidesivir confirmation was found to have the lowest binding energy (-3.73 kcal/mol) and lowest inhibition constant (58.4 M), as well as several amino acid residues in close proximity, including Asp 623, Cys 622, Tyr 619, Lys 621, and Asp 760. This study was concluded that RdRp would be a potential drug target for the promising drug Galidesivir against SARS-CoV-2 in nearest future.